Media coverage about Endocyte (NASDAQ:ECYT) has been trending somewhat positive on Friday, Accern Sentiment Analysis reports. Accern identifies negative and positive press coverage by analyzing more than twenty million news and blog sources in real time. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Endocyte earned a news impact score of 0.09 on Accern’s scale. Accern also gave news headlines about the biopharmaceutical company an impact score of 45.1422535818809 out of 100, meaning that recent press coverage is somewhat unlikely to have an impact on the company’s share price in the near term.
Here are some of the news headlines that may have impacted Accern’s rankings:
- Stocks with Performance Valuation Turns Game Changers: Endocyte, Inc. (NASDAQ:ECYT) – NASDAQ Times (nasdaqtimes.com)
- BRIEF-Peter Dodwell reports 7.1 pct passive stake in Endocyte Inc (feeds.reuters.com)
- Safe Haven Performance Portfolio Stocks Roundup: Endocyte, Inc. (NASDAQ:ECYT) – NASDAQ Times (nasdaqtimes.com)
- Endocyte, Inc. : Endocyte, Wedbush Analyst Upgrade, and the PSMA-617 Licensing Deal (4-traders.com)
Endocyte (NASDAQ:ECYT) last issued its quarterly earnings results on Tuesday, August 8th. The biopharmaceutical company reported ($0.28) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.25) by ($0.03). The business had revenue of $0.01 million during the quarter. Endocyte had a negative net margin of 61,437.14% and a negative return on equity of 32.68%. During the same period in the previous year, the business earned ($0.25) EPS.
Several equities research analysts have issued reports on the company. Wedbush raised Endocyte from a “neutral” rating to an “outperform” rating and raised their target price for the stock from $2.00 to $7.00 in a research note on Tuesday, October 3rd. ValuEngine raised Endocyte from a “strong sell” rating to a “sell” rating in a research note on Monday, October 2nd. Cowen and Company reissued a “hold” rating on shares of Endocyte in a research note on Monday, October 2nd. Finally, Zacks Investment Research cut Endocyte from a “hold” rating to a “sell” rating in a research note on Monday, August 14th. Two analysts have rated the stock with a sell rating, one has given a hold rating and two have issued a buy rating to the company. The company has an average rating of “Hold” and an average target price of $7.00.
ILLEGAL ACTIVITY NOTICE: “Endocyte (ECYT) Receiving Somewhat Favorable News Coverage, Study Finds” was reported by Markets Daily and is the sole property of of Markets Daily. If you are accessing this story on another website, it was stolen and reposted in violation of U.S. & international copyright legislation. The legal version of this story can be viewed at https://www.themarketsdaily.com/2017/10/13/endocyte-ecyt-receiving-somewhat-favorable-news-coverage-study-finds.html.
Endocyte Company Profile
Receive News & Ratings for Endocyte Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Endocyte Inc. and related companies with MarketBeat.com's FREE daily email newsletter.